Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinovac Prospers in Q2 on Large Government Order

publication date: Aug 20, 2009

Sinovac Biotech (北京科兴生物制品有限公司) prospered during its Q2, thanks largely to a single $12.8 million order for its major product, the hepatitis A vaccine Healive®. Sinovac said Q2 revenues were up 21% at $20 million while net income increased a much larger 74% to $5.8 million. Sinovac reported that 89% of the $12.8 million order was filled during Q2. That means $11.4 million of the company’s $20 million in Q2 revenues derived from the one-time event. More details...

Stock Symbol: (NYSE Amex: SVA)

 



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here